Peter Rieckmann
YOU?
Author Swipe
View article: Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering Group
Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering Group Open
For PwMS to be unburdened by symptoms, professionals and stakeholders within the MS community should work together to meet the updated MS21 vision, including access to appropriate care, greater PwMS involvement in decisions, and further re…
View article: Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression Open
Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.
View article: Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care Open
This is a summary of a previously published paper: Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. It describes a collaboration between people with multiple sclerosis (PwMS) …
View article: Can Growth Hormone Lead to a Faster Recovery from Guillain-Barré Syndrome? Case Report of the First Therapeutic Use in One Patient
Can Growth Hormone Lead to a Faster Recovery from Guillain-Barré Syndrome? Case Report of the First Therapeutic Use in One Patient Open
Although the prognosis in Guillain-Barré syndrome (GBS) is generally good, protracted and incomplete courses of recovery can be a heavy burden. Animal studies suggest growth hormone (GH) treatment could stimulate myelin repair and thus acc…
View article: Expert opinion on the pharmacological management of multiple sclerosis in women of childbearing age in Iraq
Expert opinion on the pharmacological management of multiple sclerosis in women of childbearing age in Iraq Open
Given the complexity of managing MS in pregnant women, it is the opinion of the expert panel that family planning should be discussed early in the disease course, planned pregnancy should be encouraged, and open communication with patient …
View article: Supplementary Material for: Can growth hormone lead to a faster recovery from Guillain-Barrée syndrome? Case report of the first therapeutic use in one patient
Supplementary Material for: Can growth hormone lead to a faster recovery from Guillain-Barrée syndrome? Case report of the first therapeutic use in one patient Open
Although the prognosis in Guillain-Barré syndrome (GBS) is generally good, protracted and incomplete courses of recovery can be a heavy burden. Animal studies suggest growth hormone (GH) treatment could stimulate myelin repair and thus acc…
View article: Expert Opinion On COVID-19 Vaccines and Cladribine Tablets in MS: A Plain Language Summary
Expert Opinion On COVID-19 Vaccines and Cladribine Tablets in MS: A Plain Language Summary Open
Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.
View article: Disease Stability Over Five Years in People With Multiple Sclerosis Treated With Cladribine Tablets: A Plain Language Summary
Disease Stability Over Five Years in People With Multiple Sclerosis Treated With Cladribine Tablets: A Plain Language Summary Open
Researchers concluded that a 2-year course of cladribine tablets may provide long-term benefits on disability for up to 5 years. Clinical Trial Registration: NCT00213135 (ClinicalTrials.gov) Clinical Trial Registration: NCT00641537 (Clinic…
View article: Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4 Open
Continuous monitoring of disease activity during the treatment-free period is important. Subsequent management depends on the presence or absence of inflammatory disease activity, determined in the absence of consistent guidelines via prac…
View article: The Association Between Actigraphy-Derived Behavioral Clusters and Self-Reported Fatigue in Persons With Multiple Sclerosis: Cross-sectional Study
The Association Between Actigraphy-Derived Behavioral Clusters and Self-Reported Fatigue in Persons With Multiple Sclerosis: Cross-sectional Study Open
Background Persons with multiple sclerosis frequently report increased levels of fatigue and fatigability. However, behavioral surrogates that are strongly associated with self-reports are lacking, which limits research and treatment. Obje…
View article: Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study Open
Objective Describe the long-term outcomes of early-start (ES) and delayed-start (DS) glatiramer acetate 40 mg/mL treatment three times weekly (GA40) for up to seven years in the Glatiramer Acetate Low-frequency Administration (GALA) study …
View article: Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets in Clinical Practice
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets in Clinical Practice Open
Background Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID-19 pandemic, in particular relating to COVID-…
View article: The Association Between Actigraphy-Derived Behavioral Clusters and Self-Reported Fatigue in Persons With Multiple Sclerosis: Cross-sectional Study (Preprint)
The Association Between Actigraphy-Derived Behavioral Clusters and Self-Reported Fatigue in Persons With Multiple Sclerosis: Cross-sectional Study (Preprint) Open
BACKGROUND Persons with multiple sclerosis frequently report increased levels of fatigue and fatigability. However, behavioral surrogates that are strongly associated with self-reports are lacking, which limits research and treatment. O…
View article: Speed but Not Smoothness of Gait Reacts to Rehabilitation in Multiple Sclerosis
Speed but Not Smoothness of Gait Reacts to Rehabilitation in Multiple Sclerosis Open
Introduction. Improved gait is one of the leading therapy goals in multiple sclerosis. A plethora of clinical timed trials and state-of-the-art technology-based approaches are available to assess gait performance. Objectives. To examine wh…
View article: Inpatient Rehabilitation: Prediction of Changes in Sensorimotor Performance in Multiple Sclerosis: A Pilot Study
Inpatient Rehabilitation: Prediction of Changes in Sensorimotor Performance in Multiple Sclerosis: A Pilot Study Open
Inpatient rehabilitation has been shown to be an effective intervention for sensorimotor performance in multiple sclerosis (MS) patients. So far, predictions of the rehabilitation outcomes are limited. The objective was to predict inpatien…
View article: Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice Open
Background: Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID-19 pandemic, in particular relating to COVID…
View article: Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) Open
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased unders…
View article: Expert opinion on the use of cladribine tablets in clinical practice
Expert opinion on the use of cladribine tablets in clinical practice Open
Background: Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians’ questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) …